Persistent BCR::ABL1 ‐positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome‐positive ALL

HemaSphere · Published 2026-05-01 · DOI 10.1002/hem3.70372

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1002/hem3.70372

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Expansion and safety profile of CD28‐costimulated anti‐CD19 CAR T cells in B‐cell lymphoma versus autoimmune disease · HemaSphere · 2026 · Same journal
• Publication Only · HemaSphere · 2026 · Same journal
• Polygenic scores in the diagnosis of abnormal complete blood count values · HemaSphere · 2026 · Same journal
• Real‐world, multi‐omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS) · HemaSphere · 2026 · Same journal
• From monoclonal to polyfunctional immunotherapy: Reprogramming CAR‐T‐cell therapy with oncolytic viruses in B‐cell malignancies · HemaSphere · 2026 · Same journal
• Adult TWIST2 ‐high B‐ALL confirms metabolic association but reveals molecular heterogeneity · HemaSphere · 2026 · Same journal
• Preclinical evaluation of the ROR1‐targeting antibody–drug conjugates zilovertamab vedotin and VLS‐211 against B‐cell ALL patient‐derived xenografts · HemaSphere · 2026 · Same journal
• EHA Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies · HemaSphere · 2026 · Same journal
• CAR T‐cell expansion after idecabtagene vicleucel is a predictor of outcomes in multiple myeloma · HemaSphere · 2026 · Same journal
• High‐risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas · HemaSphere · 2026 · Same journal